Capital International Investors
ALLO icon

Capital International Investors’s Allogene Therapeutics ALLO Stock Holding History

Capital International Investors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,310,109
Closed -$26.2M – 436
2023
Q1 		$26.2M Hold
5,310,109
– – 0.01% 373
2022
Q4 		$33.4M Hold
5,310,109
– – 0.01% 350
2022
Q3 		$57.3M Buy
5,310,109
+982,767
+23% +$13.4M 0.02% 328
2022
Q2 		$49.3M Buy
4,327,342
+3,740,264
+637% +$33.2M 0.01% 346
2022
Q1 		$5.35M Sell
587,078
-992,031
-63% -$10.3M ﹤0.01% 432
2021
Q4 		$23.6M Sell
1,579,109
-1,955,278
-55% -$34.5M 0.01% 397
2021
Q3 		$90.8M Buy
3,534,387
+9,273
+0.3% +$220K 0.02% 305
2021
Q2 		$91.9M Sell
3,525,114
-3,073,922
-47% -$87.7M 0.02% 306
2021
Q1 		$233M Sell
6,599,036
-529,183
-7% -$17.8M 0.06% 226
2020
Q4 		$180M Sell
7,128,219
-136,170
-2% -$4.44M 0.05% 248
2020
Q3 		$274M Buy
7,264,389
+49,476
+0.7% +$1.87M 0.08% 192
2020
Q2 		$309M Buy
7,214,913
+2,636,113
+58% +$95.3M 0.1% 169
2020
Q1 		$89M Buy
4,578,800
+690,779
+18% +$16.5M 0.04% 221
2019
Q4 		$101M Sell
3,888,021
-52,538
-1% -$1.45M 0.03% 234
2019
Q3 		$107M Buy
3,940,559
+17
+0% +$484 0.04% 221
2019
Q2 		$106M Buy
3,940,542
+1,908,988
+94% +$53.2M 0.04% 234
2019
Q1 		$58.7M Hold
2,031,554
– – 0.03% 259
2018
Q4 		$54.7M Buy
+2,031,554
New +$54M 0.03% 241

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Capital International Investors's ALLO Position: Q2 2023 in Review

Capital International Investors sold out of Allogene Therapeutics (ALLO) in Q2 2023, closing a stake of 5,310,109 shares — an estimated $26.2M sold.

Capital International Investors first reported a position in ALLO in Q4 2018 and held it in 18 quarters. The position peaked at $309M in Q2 2020. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

  • Capital International Investors reported no remaining Allogene Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Capital International Investors sold 5,310,109 Allogene Therapeutics shares in Q2 2023, an estimated $26.2M.
  • Capital International Investors first reported a position in Allogene Therapeutics in Q4 2018 and held it in 18 quarters.
  • Capital International Investors's Allogene Therapeutics position peaked at $309M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on Capital International Investors's 13F filing for Q2 2023, filed 11 Aug 2023.